PMC:7299399 / 14120-14490 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T68","span":{"begin":337,"end":344},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"ome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cell"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T61","span":{"begin":263,"end":271},"obj":"Disease"}],"attributes":[{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cell"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T165","span":{"begin":155,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T166","span":{"begin":208,"end":213},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T167","span":{"begin":244,"end":245},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T168","span":{"begin":272,"end":276},"obj":"http://purl.obolibrary.org/obo/CLO_0001236"}],"text":"ome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cell"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T80","span":{"begin":20,"end":23},"obj":"Chemical"},{"id":"T81","span":{"begin":178,"end":192},"obj":"Chemical"},{"id":"T82","span":{"begin":178,"end":187},"obj":"Chemical"},{"id":"T83","span":{"begin":188,"end":192},"obj":"Chemical"},{"id":"T84","span":{"begin":246,"end":250},"obj":"Chemical"},{"id":"T85","span":{"begin":288,"end":297},"obj":"Chemical"},{"id":"T86","span":{"begin":337,"end":344},"obj":"Chemical"}],"attributes":[{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"ome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cell"}

{"project":"LitCovid-PubTator","denotations":[{"id":"239","span":{"begin":329,"end":330},"obj":"Gene"},{"id":"240","span":{"begin":331,"end":336},"obj":"Gene"},{"id":"241","span":{"begin":263,"end":273},"obj":"Species"}],"attributes":[{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"Gene:43740568"},{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"Gene:43740568"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cell"}

{"project":"2_test","denotations":[{"id":"32519842-29251725-158477","span":{"begin":193,"end":195},"obj":"29251725"}],"text":"ome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.53 Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cell"}